Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	174.56	128.89	177.95	255.09	62.35
Short-Term Investments	34.52	151.83	0	0	37.44
Cash & Cash Equivalents	209.08	280.71	177.95	255.09	99.79
Cash Growth	-25.52%	57.75%	-30.24%	155.63%	42.29%
Receivables	0	30	0	0	0
Other Current Assets	4.97	8.51	10.95	3.49	1.54
Total Current Assets	214.06	319.22	188.9	258.58	101.33
Property, Plant & Equipment	11.53	14.46	14.86	12.67	4.76
Other Long-Term Assets	0.48	0.66	2.36	2.15	1.45
Total Long-Term Assets	12	15.12	17.21	14.82	6.22
Total Assets	226.06	334.34	206.11	273.4	107.54
Accounts Payable	7.32	13.95	12.32	8.34	7.3
Deferred Revenue	125.31	147.65	3.94	3.99	4.82
Current Debt	5.34	2.8	2.3	1.44	2.89
Other Current Liabilities	-74.33	-72.87	28.96	16.24	9.07
Total Current Liabilities	63.64	91.53	47.52	30	24.07
Long-Term Debt	28.3	33.5	35.87	15.14	4.88
Other Long-Term Liabilities	97.22	117.25	0.97	0.17	0.28
Total Long-Term Liabilities	125.52	150.75	36.85	15.31	5.15
Total Liabilities	189.16	242.28	84.37	45.31	29.22
Total Debt	33.63	36.3	38.18	16.57	7.76
Debt Growth	-7.35%	-4.91%	130.36%	113.45%	-
Retained Earnings	-826.36	-654.69	-450.48	-280.42	-192.37
Comprehensive Income	0.01	-0.15	0	0	0.03
Shareholders' Equity	36.9	92.06	121.74	228.09	78.32
Net Cash / Debt	175.45	244.41	139.77	238.52	92.03
Net Cash / Debt Growth	-28.21%	74.86%	-41.40%	159.19%	31.22%
Net Cash Per Share	1.51	2.61	1.98	3.88	2.12
Working Capital	150.42	227.69	141.38	228.58	77.26
Book Value Per Share	0.32	0.98	1.73	3.71	1.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).